BusinessLB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase InhibitorsBy Nasdaq OMXFeb 9, 2018, 2:45 PM UTC
